Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Lung cancer symbols : JNJ save search
Genmab Announces that Janssen has Received Conditional European Marketing Authorization for RYBREVANT® (amivantamab) for Patients with Advanced Non-small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations, after Failure of Platinum-base
Published: 2021-12-13 (Crawled : 09:00) - globenewswire.com
GNMSF | News | $290.34 3.83% 340
|
Health Technology
|
| O: 2.8%
H: 0.02%
C: -4.98%
JNJ | News | $148.53 -0.69% -0.14% 9.6M
|
Health Technology
|
| O: -0.41%
H: 0.0%
C: 0.0%
GMAB | News | $28.47 -0.32% -0.32% 460K
|
Health Technology
|
| O: -0.08%
H: 0.0%
C: 0.0%
rybrevant europe lung cancer authorization cancer
Genmab Announces that Janssen has Received Positive CHMP Opinion for RYBREVANT® (amivantamab) for Patients with Advanced Non-small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations, After Failure of Platinum-based Therapy
Published: 2021-10-15 (Crawled : 18:00) - globenewswire.com
GNMSF | News | $290.34 3.83% 340
|
Health Technology
|
| O: 0.53%
H: 0.91%
C: 0.91%
JNJ | News | $148.53 -0.69% -0.14% 9.6M
|
Health Technology
|
| O: 0.58%
H: 0.0%
C: 0.0%
GMAB | News | $28.47 -0.32% -0.32% 460K
|
Health Technology
|
| O: 0.41%
H: 1.23%
C: 1.07%
lung cancer positive therapy cancer chmp
Several Companies Tout Lung Cancer Breakthroughs at ESMO 2021
Published: 2021-09-20 (Crawled : 15:00) - biospace.com/
JNJ | News | $148.53 -0.69% -0.14% 9.6M
|
Health Technology
|
| O: -0.54%
H: 0.0%
C: 0.0%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: -1.35%
H: 0.0%
C: 0.0%
lung cancer cancer
New Data on RYBREVANT® (amivantamab-vmjw) in Combination with Lazertinib Show Early Activity in Patients with Non-Small Cell Lung Cancer Whose Disease Has Progressed After Both Osimertinib and Platinum-Based Chemotherapy
Published: 2021-09-19 (Crawled : 16:20) - prnewswire.com
JNJ | News | $148.53 -0.69% -0.14% 9.6M
|
Health Technology
| Email alert
Add to watchlist
disease lung cancer therapy cancer
RYBREVANT® (amivantamab-vmjw) Provides Higher Activity and Longer Duration of Response When Used in Combination with Lazertinib in Patients with Advanced EGFR-Mutant Non-Small Cell Lung Cancer Who Have Failed Osimertinib
Published: 2021-09-19 (Crawled : 16:20) - prnewswire.com
JNJ | News | $148.53 -0.69% -0.14% 9.6M
|
Health Technology
| Email alert
Add to watchlist
lung cancer cancer
Janssen Presents Phase 1 Results for RYBREVANT™ (amivantamab-vmjw) in the Treatment of Patients with Advanced Non-Small Cell Lung Cancer with MET Exon 14 Skipping Mutations
Published: 2021-08-19 (Crawled : 13:00) - biospace.com/
JNJ | News | $148.53 -0.69% -0.14% 9.6M
|
Health Technology
|
| O: -0.32%
H: 1.53%
C: 1.1%
treatment lung cancer phase 1 results cancer
Optellum Announces Strategic Collaboration With The Lung Cancer Initiative At Johnson & Johnson, Applying AI To Transform Early Lung Cancer Treatment
Published: 2021-08-18 (Crawled : 08:00) - prnewswire.com
JNJ | News | $148.53 -0.69% -0.14% 9.6M
|
Health Technology
|
| O: 0.02%
H: 0.0%
C: -1.29%
treatment lung cancer collaboration cancer
Genmab Announces that Janssen has been Granted U.S. FDA Approval for RYBREVANT™ (amivantamab-vmjw) for Patients with Metastatic Non-small Cell Lung Cancer with Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations
Published: 2021-05-21 (Crawled : 20:00) - globenewswire.com
GMAB | News | $28.47 -0.32% -0.32% 460K
|
Health Technology
| Email alert
Add to watchlist
JNJ | News | $148.53 -0.69% -0.14% 9.6M
|
Health Technology
| Email alert
Add to watchlist
fda lung cancer fda approval cancer ev growth approval
RYBREVANT™ (amivantamab-vmjw) Receives FDA Approval as the First Targeted Treatment for Patients with Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
Published: 2021-05-21 (Crawled : 19:00) - prnewswire.com
JNJ | News | $148.53 -0.69% -0.14% 9.6M
|
Health Technology
| Email alert
Add to watchlist
treatment fda lung cancer fda approval cancer approval
FDA Approves First Targeted Therapy for Subset of Non-Small Cell Lung Cancer
Published: 2021-05-21 (Crawled : 17:00) - prnewswire.com
JNJ | News | $148.53 -0.69% -0.14% 9.6M
|
Health Technology
|
| O: 0.15%
H: 0.82%
C: -0.22%
fda lung cancer therapy cancer approval fda approval
Updated Amivantamab and Lazertinib Combination Data Demonstrate Durable Responses and Clinical Activity for Osimertinib-Relapsed Patients with EGFR-Mutated Non-Small Cell Lung Cancer
Published: 2021-05-19 (Crawled : 22:00) - prnewswire.com
JNJ | News | $148.53 -0.69% -0.14% 9.6M
|
Health Technology
|
| O: -0.08%
H: 0.97%
C: 0.66%
lung cancer cancer
New Amivantamab Data from CHRYSALIS Study Show Robust Clinical Activity and Durable Responses in Patients with Metastatic or Unresectable Non-Small Cell Lung Cancer and EGFR Exon 20 Insertion Mutations
Published: 2021-01-29 (Crawled : 04:08) - prnewswire.com
JNJ | News | $148.53 -0.69% -0.14% 9.6M
|
Health Technology
|
| O: -2.9%
H: 1.06%
C: -0.69%
cancer lung cancer
Janssen to Highlight Commitment to Lung Cancer Science and Innovation with Eight Data Presentations at the International Association for the Study of Lung Cancer's 2020 World Conference on Lung Cancer
Published: 2021-01-12 (Crawled : 00:11) - prnewswire.com
JNJ | News | $148.53 -0.69% -0.14% 9.6M
|
Health Technology
|
| O: 0.06%
H: 0.14%
C: -0.21%
cancer lung cancer
Veracyte Announces Expansion of Collaboration with the Lung Cancer Initiative at Johnson & Johnson
Published: 2020-12-15 (Crawled : 16:00) - biospace.com/
JNJ | News | $148.53 -0.69% -0.14% 9.6M
|
Health Technology
|
| O: 0.62%
H: 0.5%
C: 0.38%
VCYT | News | $19.92 0.45% 0.45% 510K
|
Health Technology
|
| O: 0.45%
H: 1.17%
C: -2.62%
cancer collaboration lung cancer expansion
Janssen Submits Application to U.S. FDA Seeking Approval of Amivantamab for the Treatment of Patients with Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
Published: 2020-12-03 (Crawled : 15:00) - biospace.com/
JNJ | News | $148.53 -0.69% -0.14% 9.6M
|
Health Technology
|
| O: -0.07%
H: 1.04%
C: 0.65%
cancer fda lung cancer approval treatment application
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.